Lawsuit indicates that side effect of Wegovy caused a Kentucky woman to develop stomach paralysis and a bowel obstruction, which resulted in multiple days of hospitaliation and left her with long-term gastrointestinal damage
The lead lawyers in the Ozempic MDL may choose up to 25 additional attorneys to serve on the Plaintiffs' Committee, who will take certain actions during pretrial proceedings that benefit plaintiffs in all GLP-1 lawsuits
Necrotizing pancreatitis is caused by the death of pancreas tissue, resulting in infections and lower pancreas functionality which can limit digestion.
Findings align with warnings issued by anesthesiologists last summer about Ozempic aspiration risks, following reports of life-threatening problems caused by delayed gastric emptying during surgery.
Lawyers indicate that that questions about whether the GLP-1 RA medication label warnings adequately disclose the risk of gastroparesis and other severe injuries will play a large role in the growing litigation.
Eli Lilly failed to warn users that side effects of Trulicity may cause gastroparesis, despite numerous studies, case reports and medical literature indicating that users may experience severe stomach paralysis.
Lawsuit indicates that Novo Nordisk fails to adequately disclose serious risks, indicating some doctors estimate 10% of users discontinue due the severity of the Ozempic side effects.
Health experts urge women not to use Ozempic or similar drugs to increase fertility, due to increased risks of birth defects and miscarriage.
The U.S. District Judge recently appointed to preside over all federal GLP-1 RA lawsuits is expected to appoint a group of Ozempic lawyers to take certain actions during the MDL proceedings that benefit all plaintiffs.
FDA approved expanded use of Wegovy for cardiovascular disease caused by being overweight, as concerns continue to grow about reports of stomach paralysis injuries some users are experiencing.
